Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-10-03
2006-10-03
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
07115594
ABSTRACT:
This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. This compound also increases both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.
REFERENCES:
patent: 5587497 (1996-12-01), DeLuca et al.
patent: 5843928 (1998-12-01), Deluca et al.
The Merck Manual, Sixteenth Edition, 1992, p. 1357.
Boris et al, “Relative Activities of Some Metabolites and Analogs of Cholecalciferol in Stimulation of Tibia Ash Weight in Chicks Otherwise Deprived of Vitamin D,” Vitamin D Metabolites, Analogs and Bone Ash, 1976, pp. 194-198.
Hedlund et al, “Increased Incidence of Hip Fracture in Osteoporotic Women Treated with Sodium Fluoride,” Journal of Bone and Mineral Research, vol. 4, No. 2, 1989, pp. 223-225.
Holick et al, Harrison's Principle of Internal Medicine, 13th Ed. 1994, pp. 2137-2151.
Jensen et al, “Treatment of Post Menopausal Osteoporosis, A Controlled Therapeutic Trial Comparing Oestrogen/Gestagen, 1.25-Dihydroxy-Vitamin D-3 and Calcium,” Clinical Endocrinology, 16, 1982, pp. 515-524.
Meunier, “Evidence-Based Medicine and Osteoporosis: A Comparison of Fracture Risk Reduction Data from Osteoporosis Randomised Clinical Trials,” IJCP, vol. 53, No. 2, Mar. 1999.
Nordin et al, “The Metabolic Basis of Osteoporosis,” Osteoporosis: Physiological Basis, Assessment, and Treatment, Elsevier Science Publishing Co., Inc., 1990, pp. 23-36.
Ott et al, “Calcitriol Treatment is not Effective in Postmenopausal Osteoporosis,” Annals of Internal Medicine, vol. 110, No. 4, Feb. 15, 1989, pp. 267-274.
Peck, “The Pathogenesis of Postmenopausal Osteoporosis,” Osteoporosis: Physiological Basis, Assessment, and Treatment, Elsevier Science Publishing Co., Inc., 1990, pp. 3-6.
Riggs et al, “Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures without Commensurate Increases in Bone Density,”Journal of Bone and Mineral Research, vol. 17, No. 1, 2002, pp. 11-13.
Riggs et al, “Causes of Age-Related Bone Loss and Fractures,” Osteoporosis: Physiological Basis, Assessment, and Treatment, 1990, pp. 7-16.
Christensen, Abstract PMID: 6795047, “Effect of 1,25-Dihydroxy-Vitamin D3 in Itself or Combined with Hormone Treatment in Prevent Postmenopausal Osteoporosis,” Eur. J. Clin. Invest., Aug. 11, 1981, vol. 11, No. 4.
Klein, “Nutritional Rickets and Osteomalacia,” Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 1996, pp. 301-305.
Kleerekoper, “Treatment of Osteoporosis with Sodium Fluoride Alternating with Calcium and Vitamin D,” Osteoporosis: Recent Advances in Pathogenesis and Treatment, 1981, pp. 441-448.
Sarkar, “Relationships Between Bone Mineral Desnity and Incident Vertebral Fracture Risk with Raloxifene Therapy,” Journal of Bone and Mineral Research, vol. 17, No. 1, 2002, pp. 1-10.
Cummings et al, “Improvement in Spine Bone Desity and Reduction in Risk of Vertebral Fractures During Treatment with Antiresorptive Drugs,” The American Journal of Medicine, vol. 112, 2002, pp. 281-289.
Sudhaker Rao et al, “Metabolic Bone Disease in Gastrointestinal Hepatobiliary, and Pancreatic Disorders,” Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 1996, pp. 306-311.
Watts et al, “Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis,” The New England Journal of Medicine, vol. 323, No. 2, Jul. 12, 1990, pp. 73-79.
Harris, “Four-Year Study of Intermittent Cyclic Etidronate Treatment of Postmenopausal Osteoporosis: Three Years of Blinded Therapy Followed by One Year of Open Therapy,” The American Journal of Medicine, vol. 95, Dec. 1993, pp. 557-567.
DeLuca Hector F.
Smith Connie M.
Andrus Sceales Starke & Sawall LLP
Hui San-Ming
Wisconsin Alumni Research Foundation
LandOfFree
Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3665535